Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes

BACKGROUND: Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-administered to cancer patients as part of a DC-based vaccine, are being widel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ioannou, Kyriaki, Derhovanessian, Evelyna, Tsakiri, Eleni, Samara, Pinelopi, Kalbacher, Hubert, Voelter, Wolfgang, Trougakos, Ioannis P, Pawelec, Graham, Tsitsilonis, Ourania E
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2013
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3852324/
https://ncbi.nlm.nih.gov/pubmed/24053720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2172-14-43
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg